CHARLES BAUM is listed as an executive officer and director on 3 SEC Form D filings by 2 issuers between Nov 2012 and Apr 2026: Terremoto Biosciences, Inc. (South San Francisco, CA — biotechnology — 2026; $40.7M reported sold to 14 investors) and MethylGene Inc. (Montreal, Quebec, Canada (as filed: A8) — biotechnology — 2012; $35.6M reported sold to 20 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 14 years. Across those companies the filings report $76.3M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 5 bankruptcy cases matching the name listed in Key records below.
What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for CHARLES BAUM and found 5 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Charles Baum" (MA) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.